SAN ANTONIO Postmenopausal women with hormone receptor positive breast cancer who underwent additional years of extended anastrozole therapy received no additional benefit compared with women who underwent additional years of therapy, according to data from the ABCSG .An additional years of aromatase inhibitor therapy after years of adjuvant endocrine therapy failed to improve disease free survival compared with an additional years of aromatase inhibitor therapy in postmenopausal women with hormone receptor positive breast cancer, according to the results of the .Extended endocrine therapy with an aromatase inhibitor did not improve disease free survival in patients with hormone receptor positive breast cancer enrolled in three stu.s presented at the San Antonio Breast Cancer Symposium. The results stand in contrast to the phase III National Cancer .The benefit of years of adjuvant endocrine therapy for women with hormone receptor positive HR breast cancer BC is beyond discussion. Nevertheless, the risk of recurrence of luminal BC persists for years or more after diagnosis. Consequently, approaches of extended adjuvant therapy have .
Related posts to Extended adjuvant therapy fails to improve outcomes in HR-positive breast cancer
There is a paucity of randomized controlled stu.s in the management of gallbladder cancer in relationship with systemic therapy due to the rarity of gallbladder and .
Get the latest news andysis in the stock market today, including national and world stock market news, business news, financial news and more..
Contact Us. We would love to hear from you! Please send us an email at IbmsInternational@Startmail.com.
Stig Larsen of Norwegian University of Life Sciences NMBU , s with expertise in Statistics, Oncology, Gastroenterology. Read publications, answers, and .